News: Actavis PLC (ACT)

ACT on New York Consolidated

301.53USD
31 Mar 2015
Change (% chg)

$-3.23 (-1.06%)
Prev Close
$304.76
Open
$303.52
Day's High
$304.80
Day's Low
$301.52
Volume
1,293,575
Avg. Vol
3,254,068
52-wk High
$317.72
52-wk Low
$184.71

Search Stocks
Select another date:

Tue, Mar 17 2015

EU mergers and takeovers (March 17)

BRUSSELS, March 17 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

BRIEF-American Airlines to join S&P 500

March 16 - * S&P Dow jones indices says American Airlines Group Inc to replace

Actavis loses bid for insurance in 'pill mill' case

- A federal judge has ruled that a group of insurers does not have to indemnify Actavis plc against a lawsuit filed by West Virginia accusing the drug company of selling addictive painkillers and other prescription drugs to so-called pill mills.

Eli Lilly loses Alimta drug patent case in Germany to Actavis

- Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine.

Eli Lilly loses Alimta drug patent case in Germany to Actavis

- Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine.

UPDATE 1-Eli Lilly loses Alimta drug patent case in Germany to Actavis

March 6 - Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine.

Eli Lilly loses Alimta drug patent case in Germany to Actavis

March 6 - Eli Lilly said on Friday it had lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine.

EU mergers and takeovers (March 5)

BRUSSELS, March 5 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

BRIEF-U.S. judge for Teva in patent litigation concerning Atelvia

March 4 - * U.S. judge rules in favor of Teva Pharmaceutical Industries Ltd and

TREASURIES-Bond prices slip on corporate supply; U.S. data eyed

* Traders await monthly U.S. jobs report (New throughout, updates prices, adds comments)

Select another date:
Search Stocks